JCU - Abstracts of the BAUS 2018 Scientific Meeting - June 2018 - 67

Abstracts

infections from days 2 to 6, sepsis from days 2 to 6, and
septic shock from days 3 to 6 (table 1). Laparoscopic
route caused both lower CRP levels and lower rate of
septic shock compared to open (Fisher's exact test;
p=0.012).

Conclusions: CRP has high discriminatory power as a
marker of infection from post-operative days 2 to 6.
Procedure and route have a large influence on CRP from
day 1 and should be considered when evaluating what is
abnormal.

P7-3: Table 1. Receiver operator characteristics for CRP levels on post-operative days 1 to 10. AUC = area under curve.
Day of CRP

1 (n=104)
2 (n=108)
3 (n=95)
4 (n=88)
5 (n=75)
6 (n=56)
7 (n=37)
8 (n=24)
9 (n=11)
10 (n=8)

Infective Complication

Sepsis

AUC

0.612
0.674
0.661
0.692
0.669
0.721
0.641
0.630
0.444
0.286

0.073
0.003
0.009
0.003
0.012
0.004
0.144
0.297
0.814
0.513

0.620
0.699
0.698
0.740
0.731
0.804
0.740
0.741
0.625
0.667

0.075
0.002
0.002
<0.001
0.001
<0.001
0.014
0.046
0.540
0.505

0.539
0.631
0.758
0.874
0.942
0.857
0.834
0.812
0.643
0.533

0.793
0.283
0.035
0.002
<0.0001
0.005
0.017
0.053
0.450
0.881

P7-4 The first experience in the United
Kingdom of using the novel treatment
uromune® in men with recurrent Urinary
Tract Infections
Yang B1, Foley S1, Charlesworth P1
1Urology at Royal Berkshire Hospital, Reading, United Kingdom

Introduction: UTIs are the most common infections
worldwide, affecting significant numbers of men. Men with
recurrent UTIs often rely on prolonged courses of
antibiotics.
The alarming rise of antibiotic resistance (described as
one of the biggest risks to global health in our lifetime) has
triggered a Global Action Plan from the WHO, providing a
pressing need to find viable alternatives. We present the
first experience in the UK of the immunomodulating liveattenuated sublingual bacterial vaccine Uromune® in a
preliminary cohort of men with recurrent UTIs.
Method: 14 men (mean: 65years, range: 44-84) with recurrent UTIs received 3 months of Uromune®. 2 men had
significant PVRs, 1 had a Mitrofanoff and 1 had bladder
neck stenosis post prostatectomy. All 5 perform ISC regularly. Follow-up for up to 12 months was by a specialist
phone consultation and an ongoing number. No antibiotic
prophylaxis was used throughout.
Results: All 14 men completed treatment. 10/14 (71%)
reported no UTIs during the treatment and follow-up. Of
the 4 men with recurrences, one had significant PVR and
one had bladder neck stenosis. There were no reported
side effects.

Septic Shock

Conclusions: This initial cohort suggest that Uromune®
is safe and effective in men with recurrent UTIs, offering a
potentially viable alternative to antibiotic prophylaxis.
Uromune® is effective in men with structural abnormalities, but less compared to a normal urinary tract, though
the numbers are small. These preliminary results supports
the creation of an international multi-centre trial to further investigate Uromune® in larger groups of men with
longer follow-ups.
P7-5 The contemporary management of
traumatic renal injury at a UK major trauma
centre
Georgiades 1, Aldiwani M1, Omar I1, Angel-Scott H1,
Vale J1, Mayer E1
1St Mary's Hospital, Imperial College Healthcare NHS Trust,
London, United Kingdom

Introduction: With the introduction of the Major Trauma
Centre (MTC) network, there has been an increased
exposure to renal injury; commonly in conjunction with
polytrauma. Conservative management and advances in
interventional radiology (IR) methods, reduces the rate of
surgical exploration and preserves injured kidneys.
Aims: To analyse the success of contemporary management of renal injury following trauma in our MTC.
Materials and Methods: The prospectively maintained
Trauma Audit and Research Network (TARN) database
was interrogated to identify patients with urinary tract
injuries between January 2014 and November 2016.

Table of Contents for the Digital Edition of JCU - Abstracts of the BAUS 2018 Scientific Meeting - June 2018